Elevance Health stock faces 2027 test after raised 2026 outlook

Elevance Health reported stronger-than-expected third-quarter results on October 21, 2026, and raised its full-year outlook. The insurer said operating performance improved across its portfolio, while its 2027 plan starts from a higher earnings baseline.

Elevance Health stock traded at 385.90 euros on Lang & Schwarz at 13:41 CET on Wednesday, November 11.

Higher earnings outlook after Q3

In its third-quarter results release, Elevance reported operating revenue of 50.4 billion US dollars, up 0.7 percent from the year-earlier quarter. Adjusted diluted earnings per share reached 6.99 US dollars, compared with diluted GAAP EPS of 6.27 US dollars. The company said the result included a net non-operating benefit of 1.85 US dollars per share.

Management raised 2026 adjusted diluted EPS guidance to at least 29.00 US dollars from continued operating momentum. The company also lifted its operating cash flow outlook to at least 6.5 billion US dollars. Elevance said its 2026 earnings baseline now stands at least 26.75 US dollars, excluding non-recurring net investment income, other non-operating items and targeted one-time investments.

Carelon supports operating performance

Carelon generated third-quarter operating revenue of 19.3 billion US dollars, an increase of 5 percent from the prior year. Operating gain rose 17 percent to 0.9 billion US dollars, helped by Carelon Services risk-based solutions and improved specialty pharmacy profitability.

The Health Benefits segment produced 43.4 billion US dollars in revenue, 3 percent more than a year earlier. Higher premium yields and service-fee revenue offset lower membership in Medicare Advantage, Medicaid and employer risk-based plans. The enterprise benefit expense ratio improved by 70 basis points to 90.6 percent, while the adjusted operating expense ratio increased by 90 basis points to 11.3 percent as Elevance invested in capabilities and growth initiatives.

Membership remains a key watchpoint

Medical membership totaled approximately 44.9 million at September 30, 2026, down 487,000 from the prior year. Lower enrollment in Medicaid, Medicare Advantage and employer risk-based businesses more than offset growth in commercial fee-based membership.

For investors, the raised outlook improves the near-term earnings picture but does not remove execution risks. The company is targeting at least 12 percent adjusted EPS growth in 2027 from its higher baseline, making medical-cost control, premium-rate development and membership trends central indicators for the next reporting cycle.

Elevance also declared a fourth-quarter dividend of 1.72 US dollars per share. The payment is scheduled for December 18, 2026, to shareholders of record at the close of business on December 4.

The broader S&P 500 market remains an important backdrop for large US healthcare stocks.

For more news and analyses on Elevance Health stock, investors will next focus on the company's detailed 2027 assumptions and the next quarterly report.

Elevance Health at a Glance

• Company: Elevance Health Inc.
• ISIN: US0367521038
• Ticker: ELV
• Home exchange: New York Stock Exchange
• Lang & Schwarz quote: 385.90 euros on November 11, 2026, at 13:41 CET
• 2026 adjusted EPS outlook: At least 29.00 US dollars
• 2026 operating cash flow outlook: At least 6.5 billion US dollars